Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Discontinued Operations (Tables)

Note 11 - Discontinued Operations (Tables)

3 Months Ended

Mar. 31, 2016

Notes Tables

Schedule of Components of Loss from Discontinued Operations [Table Text Block]

		Three Months Ending March 31,
		2016				2015
Revenue, net		$	1,644			$	36,463

(Loss) income from discontinued operations, before tax			(735	)*			3,118
Income tax expense			45				1
(Loss) income from discontinued operations, net of tax		$	(780	)		$	3,117

Discontinued Operation, Schedule of Amounts Recognized in Balance Sheet [Table Text Block]

		For the Three Months Ended March 31, 2016												For the Year Ended December 31, 2015
		CSO				DCA/ TVG				Total				CSO				DCA/ TVG				Total
Accounts receivable, net		$	735			$	-			$	735			$	3,296			$	-			$	3,296
Unbilled receivable, net			-				-				-				16				-				16
Other			795				-				795				2,062				-				2,062
Current assets from discontinued operations			1,530				-				1,530				5,374				-				5,374
Property and equipment, net			33				-				33				190				-				190
Other			-				150				150				-				150				150
Long-term assets from discontinued operations			33				150				183				190				150				340
Total assets		$	1,563			$	150			$	1,713			$	5,564			$	150			$	5,714

Accounts payable		$	2,195			$	-			$	2,195			$	3,767			$	-			$	3,767
Unearned contract revenue			-				-				-				11				-				11
Accrued salary and bonus			2,219				-				2,219				3,036				-				3,036
Other			1,812				288				2,100				5,092				358				5,450
Current liabilities from discontinued operations			6,226				288				6,514				11,906				358				12,264
Total liabilities		$	6,226			$	288			$	6,514			$	11,906			$	358			$	12,264